Literature DB >> 8565282

Generalized immune activation in pulmonary tuberculosis: co-activation with HIV infection.

G Vanham1, K Edmonds, L Qing, D Hom, Z Toossi, B Jones, C L Daley, B Huebner, L Kestens, P Gigase, J J Ellner.   

Abstract

Parameters of immune activation/differentiation were studied in a group of newly diagnosed HIV- and HIV+ pulmonary tuberculosis (TB) patients. Compared with controls, HLA-DR expression on both CD4 and CD8 T cells from the HIV- TB patients was approximately doubled; HLA-DR on T cells from the HIV+ group was tripled. The monocytes from both groups of patients expressed abnormally high levels of the Fc gamma receptors I and III. Serum levels of tumour necrosis factor-alpha (TNF-alpha), neopterin and beta 2-microglobulin were increased in HIV- and even more so in HIV+ TB patients. The expression of HLA-DR on T cell subsets and of Fc gamma R on monocytes correlated with each other, but not with serum activation markers. This pattern of non-specific activation during TB infection may be associated with enhanced susceptibility to HIV infection.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8565282      PMCID: PMC2200321          DOI: 10.1046/j.1365-2249.1996.907600.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  50 in total

1.  Surface phenotype analysis of CD16+ monocytes from leukapheresis collections for peripheral blood progenitors.

Authors:  M Tanaka; J Honda; Y Imamura; K Shiraishi; K Tanaka; K Oizumi
Journal:  Clin Exp Immunol       Date:  1999-04       Impact factor: 4.330

2.  Incorporation of HLA-DR into the envelope of human immunodeficiency virus type 1 in vivo: correlation with stage of disease and presence of opportunistic infection.

Authors:  S D Lawn; S T Butera
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

Review 3.  Immunoregulation in TB: observations and implications.

Authors:  Jerrold J Ellner
Journal:  Clin Transl Sci       Date:  2010-02       Impact factor: 4.689

4.  Selective depletion of CD14+ CD16+ monocytes by glucocorticoid therapy.

Authors:  G Fingerle-Rowson; M Angstwurm; R Andreesen; H W Ziegler-Heitbrock
Journal:  Clin Exp Immunol       Date:  1998-06       Impact factor: 4.330

Review 5.  Cytokines, plasma immune activation markers, and clinically relevant surrogate markers in human immunodeficiency virus infection.

Authors:  J L Fahey
Journal:  Clin Diagn Lab Immunol       Date:  1998-09

6.  Alterations in the number of circulating leucocytes, phenotype of monocyte and cytokine production in patients undergoing cardiothoracic surgery.

Authors:  M J Hiesmayr; A Spittler; A Lassnigg; R Berger; G Laufer; A Kocher; O Artemiou; G Boltz-Nitulescu; E Roth
Journal:  Clin Exp Immunol       Date:  1999-02       Impact factor: 4.330

7.  Expanded CD14+ CD16+ monocyte subpopulation in patients with acute and chronic infections undergoing hemodialysis.

Authors:  W A Nockher; J E Scherberich
Journal:  Infect Immun       Date:  1998-06       Impact factor: 3.441

8.  Expansion of a subset of CD14highCD16negCCR2low/neg monocytes functionally similar to myeloid-derived suppressor cells during SIV and HIV infection.

Authors:  Lucio Gama; Erin N Shirk; Julia N Russell; Karina I Carvalho; Ming Li; Suzanne E Queen; Jorge Kalil; M Christine Zink; Janice E Clements; Esper G Kallas
Journal:  J Leukoc Biol       Date:  2012-02-24       Impact factor: 4.962

9.  Induction of HIV type 1 expression correlates with T cell responsiveness to mycobacteria in patients coinfected with HIV type 1 and Mycobacterium tuberculosis.

Authors:  David H Canaday; Mianda Wu; Shigou Lu; Htin Aung; Pierre Peters; Joy Baseke; Wilma Mackay; Harriet Mayanja-Kizza; Zahra Toossi
Journal:  AIDS Res Hum Retroviruses       Date:  2009-02       Impact factor: 2.205

10.  Monocytes and neutrophils from tuberculosis patients are insensitive to anti-inflammatory effects triggered by the prototypic formyl peptide N-formyl-methionyl-leucyl-phenylalanine (FMLP).

Authors:  M Beigier-Bompadre; M Alemán; P Barrionuevo; M C Franco; C J Rubel; M Del C Sasiain; M S Palermo; E Abbate; M A Isturiz
Journal:  Clin Exp Immunol       Date:  2003-08       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.